Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
2.170
+0.100 (4.83%)
Aug 15, 2025, 10:57 AM - Market open
Esperion Therapeutics Employees
Esperion Therapeutics had 304 employees as of December 31, 2024. The number of employees increased by 64 or 26.67% compared to the previous year.
Employees
304
Change (1Y)
64
Growth (1Y)
26.67%
Revenue / Employee
$881,990
Profits / Employee
-$342,178
Market Cap
437.52M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 304 | 64 | 26.67% |
| Dec 31, 2023 | 240 | 41 | 20.60% |
| Dec 31, 2022 | 199 | -19 | -8.72% |
| Dec 31, 2021 | 218 | -261 | -54.49% |
| Dec 31, 2020 | 479 | 286 | 148.19% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ESPR News
- 7 days ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 24 days ago - Esperion to Report Second Quarter 2025 Financial Results on August 5 - GlobeNewsWire
- 6 weeks ago - Esperion Appoints Craig Thompson to Board of Directors - GlobeNewsWire
- 2 months ago - Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics? - Seeking Alpha
- 3 months ago - Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - GlobeNewsWire
- 3 months ago - Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference - GlobeNewsWire